Illumina has appointed Daniel Grosu as Chief Medical Officer, a newly created position at the company. Grosu will play a key role in building Illumina’s diagnostic capabilities through collaborations with regulatory agencies, internal product development teams, and Illumina’s CLIA-certified clinical laboratory, the company said.
Prior to joining Illumina, Grosu was group director of clinical science and clinical and medical affairs at Ortho-Clinical Diagnostics. He also was previously the director and leader of global clinical development and diagnostic imaging at Bayer Healthcare Pharmaceuticals. Grosu also has worked for Siemens Medical Solutions.